Your browser doesn't support javascript.
loading
Production of intravenous human dengue immunoglobulin from Brazilian-blood donors
Gouveia, Frederico Leite; Oliveira, Renata Mendes Batista de; Lucena, Antônio Edson de Souza; Cordeiro, Marli Tenório; Leite, Ana Cristina Lima.
  • Gouveia, Frederico Leite; Federal University of Pernambuco. Department of Pharmaceutical Sciences.
  • Oliveira, Renata Mendes Batista de; Federal University of Pernambuco. Department of Pharmaceutical Sciences.
  • Lucena, Antônio Edson de Souza; Federal University of Pernambuco. Department of Pharmaceutical Sciences.
  • Cordeiro, Marli Tenório; Federal University of Pernambuco. Department of Pharmaceutical Sciences.
  • Leite, Ana Cristina Lima; Federal University of Pernambuco. Department of Pharmaceutical Sciences.
Braz. j. pharm. sci ; 49(4): 821-829, Oct.-Dec. 2013. ilus, tab
Article in English | LILACS | ID: lil-704114
ABSTRACT
Dengue represents an important health problem in Brazil and therefore there is a great need to develop a vaccine or treatment. The neutralization of the dengue virus by a specific antibody can potentially be applied to therapy. The present paper describes, for the first time, the preparation of Immunoglobulin specific for the dengue virus (anti-DENV IgG), collected from screened Brazilian blood-donations. Production was performed using the classic Cohn-Oncley process with minor modifications. The anti-DENV IgG was biochemically and biophysically characterized and fulfilled the requirements defined by the European Pharmacopoeia. The finished product was able to neutralize different virus serotypes (DENV-1, DENV-2, and DENV-3), while a commercial IgG collected from American blood donations was found to have low anti-dengue antibody titers. Overall, this anti-DENV IgG represents an important step in the study of the therapeutic potential and safety of a specific antibody that neutralizes the dengue virus in humans.
RESUMO
A dengue representa um importante problema de saúde no Brasil, portanto, a identificação de vacina ou tratamento eficaz é uma necessidade urgente. A neutralização do vírus da dengue, por anticorpo específico, tem potencial aplicação terapêutica. Descrevemos aqui, pela primeira vez, a preparação de imunoglobulina específica para o vírus da dengue (IgG anti-DENV), produzida a partir do plasma selecionado de doadores brasileiros. A produção foi realizada utilizando o método clássico de Cohn-Oncley com pequenas modificações. A IgG anti-DENV foi bioquimicamente e biofisicamente caracterizada e cumpriu os requisitos definidos pela Farmacopeia Europeia. O produto final foi capaz de neutralizar diferentes sorotipos do vírus (DENV-1, DENV-2 e DENV-3), enquanto que a IgG comercial, produzida a partir do plasma de doadores americanos, apresentou baixos títulos de anticorpos anti-dengue. No geral, esta IgG anti-DENV representa uma importante etapa para o estudo do potencial terapêutico e segurança da neutralização, por anticorpos específicos, do vírus da dengue em humanos.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Blood Donors / Immunoglobulins, Intravenous / Dengue Country/Region as subject: South America / Brazil Language: English Journal: Braz. j. pharm. sci Year: 2013 Type: Article / Project document Affiliation country: Brazil

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Blood Donors / Immunoglobulins, Intravenous / Dengue Country/Region as subject: South America / Brazil Language: English Journal: Braz. j. pharm. sci Year: 2013 Type: Article / Project document Affiliation country: Brazil